P056 DIFFERENCE IN CLINICAL EFFICACY AND SAFETY PROFILE IN CROHN’S DISEASE PATIENTS TREATED WITH INFLIXIMAB ACCORDING TO TIMING FOR ADDITION OF THIOPURINE

Although clinical efficacy of combination therapy with infliximab (IFX) and thiopurine has been demonstrated in Crohn’s disease (CD), it remains uncertain when to add thiopurine in CD patients treated with IFX. The present study aimed to clarify appropriate timing for the addition of thiopurine in CD patients treated with IFX.